Table 3 Univariate and multivariate analyses of overall survival
Characteristic | n | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | ||
Age (years) | – | 1.07 | 0.95–1.21 | 0.24 | – | – | – |
Sex | |||||||
Male | 45 | 1.00 | – | – | 1.00 | – | – |
Female | 19 | 0.38 | 0.15–0.99 | 0.04* | 1.85 | 0.48–7.18 | 0.38 |
BMI (kg/m2) | – | 0.97 | 0.86–1.10 | 0.65 | – | – | – |
ECOG PS | – | 1.53 | 1.06–2.21 | 0.02* | 1.26 | 0.84–1.89 | 0.26 |
GOLD stage† | |||||||
Normal + I | 42 | 1.00 | – | – | – | – | – |
II + III | 17 | 1.50 | 0.72–3.11 | 0.28 | – | – | – |
FEV1.0 (L) † | 0.46 | 0.20–1.06 | 0.07 | – | – | – | |
History of lung operation | |||||||
No | 50 | 1.00 | – | – | – | – | – |
Yes | 14 | 1.49 | 0.68–3.24 | 0.32 | – | – | – |
Charlson Comorbidity Index | – | 1.09 | 0.87–1.37 | 0.45 | – | – | – |
Operable | |||||||
No | 48 | 1.00 | – | – | 1.00 | – | – |
Yes | 16 | 0.20 | 0.06–0.66 | 0.008** | 0.25 | 0.07–0.86 | 0.03* |
Tumor diameter (cm) | 0.99 | 0.64–1.52 | 0.96 | – | – | – | |
ITV (mL) | – | 1.00 | 0.97–1.03 | 0.96 | – | – | – |
PTV (mL) | – | 1.00 | 0.98–1.01 | 0.83 | – | – | – |
T stage | – | 1.16 | 0.88–1.53 | 0.29 | – | – | – |
Histology | |||||||
Adenocarcinoma | 43 | 1.00 | – | – | 1.00 | – | – |
SCC + NSCLC | 22 | 3.14 | 1.56–6.31 | 0.001** | 1.97 | 0.95–4.10 | 0.07 |
Tumor appearance | |||||||
Pure GGN + part-solid GGN | 20 | 1.00 | – | – | 1.00 | – | – |
Solid | 45 | 5.52 | 1.68–18.14 | 0.005** | 5.76 | 1.05–31.71 | 0.04* |
Total dose (Gy) | |||||||
48 | 59 | 1.00 | – | – | – | – | – |
60 | 6 | 0.94 | 0.83–1.06 | 0.29 | – | – | – |
Prescribed dose | |||||||
Isocenter | 47 | 1.00 | – | – | – | – | – |
D95 | 18 | 0.48 | 0.14–1.64 | 0.24 | – | – | – |